The Sound Of Opportunity: Novartis Inks Deal With GenVec For Hearing Loss R&D
This article was originally published in The Pink Sheet Daily
Executive Summary
GenVec's gene-based program targets a hearing loss world ruled by devices.
You may also be interested in...
Say Again? Startups Aim To Develop Drug Options For Hearing Loss Market
A host of venture-backed drug makers are racing to pass the proof-of-concept hurdle and attract big-pharma deals, which so far have been sparse.
Say Again? Startups Aim To Develop Drug Options For Hearing Loss Market
A host of venture-backed drug makers are racing to pass the proof-of-concept hurdle and attract big-pharma deals, which so far have been sparse.
Novartis Secures Ophthalmic Diversity With Final Alcon Buyout
Novartis' new eye care division, created by folding together Alcon, CIBA Vision and some of the Swiss pharma's own ophthalmic therapies, will control more than 70 percent of the global eye care market at its inception. And it has a range of pipeline projects in the works to support that hegemony going forward